Human CD25 ELISA Kit

Contact us
Diaclone
Product Code: 950.500.192
Product Group: ELISA Kits
Supplier: Diaclone
CodeSizePrice
950.500.1922 x 96 (pre-coated)£570.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Human
Regulatory Status: RUO
Application: Enzyme-Linked Immunosorbent Assay (ELISA)

Further Information

Antigen Synonyms:
IL-2R
Assay Range:
68.75-2200 pg/ml
Cross reaction:
No cross reactivity with other human soluble receptors
Description:
Diaclone ELISA Kits include pre-coated strip plates biotinylated secondary antibody standards controls (where applicable) buffers streptavidin-HRP TMB stop reagents and a detailed procedure.
Detection Target:
CD25 / IL-2R
Incubation:
3h45
Reactivity:
Human
Research Area:
Cytokine / Chemokine Receptors
Sample Size:
100 µl
Sample Types:
Serum Plasma Cell culture supernatant
Sensitivity:
8 pg/ml
Specificity:
Recognizes both natural and recombinant human soluble IL-2R

References

  1. Shokripour M. et al. J Educ Health Promot. 2020; 9: 48. . Association of soluble interleukin-2 receptor alpha with laboratory parameters and clinical findings of hemophagocytic lymphohistiocytosis patients: The first report from South of Iran. https://pubmed.ncbi.nlm.nih.gov/32318616/
  2. Leotta S. et al. Front Immunol. 2019; 10: 3158. . Preliminary Results of a Combined Score Based on sIL2-Rα and TIM-3 Levels Assayed Early After Hematopoietic Transplantation. https://pubmed.ncbi.nlm.nih.gov/32117211/
  3. Betjes M. G. H. et al. Nephrol. Dial. Transplant2015: gfv092. Encapsulating peritoneal sclerosis is associated with T-cell activation. https://www.ncbi.nlm.nih.gov/pubmed/25934991
  4. Botella-Carretero J. I. et al. Eur. J. Endocrinol. 2005; 153(2): 223 - 230. The effects of thyroid hormones on circulating markers of cell-mediated immune response as studied in patients with differentiated thyroid carcinoma before an during thyroxine withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/16061828
  5. Christiansson L. et al.PLoS One2013; 8(1): e55818. Increased level of myeloid-derived suppressor cells programmed death receptor ligand 1/programmed death receptor 1 and soluble CD25 in Sokal high risk chronic myeloid leukemia.. https://www.ncbi.nlm.nih.gov/pubmed/23383287
  6. Dennert R. et al. Clin. Vaccine Immunol.2012; 19(8): 1182-1187. Differences in Virus Prevalence and Load in the Hearts of Patients with Idiopathic Dilated Cardiomyopathy with and without Immune-Mediated Inflammatory Diseases. https://www.ncbi.nlm.nih.gov/pubmed/22695157
  7. Eurelings L.E.M. et al.PLoS One. 2019 Oct 17;14(10):e0223897. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis.. https://www.ncbi.nlm.nih.gov/pubmed/31622413
  8. Foussat A. et al. Blood 2001; 98(6): 1678 - 1686. Deregulation of the expression of the fractalkine/fractalkine receptor complex in HIV-1-infected patients. https://www.ncbi.nlm.nih.gov/pubmed/11535497
  9. Gao Z. et al.Mediterr J Hematol Infect Dis. 2019 Jan 1;11(1):e2019008.. Soluble ST2 and CD163 as Potential Biomarkers to Differentiate Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome.. https://www.ncbi.nlm.nih.gov/pubmed/30671214
  10. Groen-Hakan F. et al.JAMA Ophthalmol. 2017 Dec 1;135(12):1352-1358.. Diagnostic Value of Serum-Soluble Interleukin 2 Receptor Levels vs Angiotensin-Converting Enzyme in Patients With Sarcoidosis-Associated Uveitis.. https://www.ncbi.nlm.nih.gov/pubmed/29121154
  11. Karim A.F. et al.Mediators Inflamm. 2018 Mar 1;2018:6103064.. Soluble Interleukin-2 Receptor: A Potential Marker for Monitoring Disease Activity in IgG4-Related Disease.. https://www.ncbi.nlm.nih.gov/pubmed/29686532
  12. Lindqvist C. A. et al.Immunology2010; 131(3): 371-6. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies.. https://www.ncbi.nlm.nih.gov/pubmed/20518821
  13. Magnusson M. K. et al.United European Gastroenterology Journal2013: 2050640613502962. CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitis. https://www.ncbi.nlm.nih.gov/pubmed/24917999
  14. Malmstrom P.-U. et al. Clin. Cancer Res.2010; 16(12): 3279-3287. AdCD40L Immunogene Therapy for Bladder Carcinoma--The First Phase I/IIa Trial. https://www.ncbi.nlm.nih.gov/pubmed/20448220
  15. Marcellis R.G.J. et al. Eur. Respir. J. 2011; 38: 628 - 634. Exercise capacity muscle strength and fatigue in sarcoidosis. https://www.ncbi.nlm.nih.gov/pubmed/21436356